Supply Chain
New research from Advisory Board, conducted in partnership with Staples Business, reveals how 102 health system supply chain and executive…
The Food and Drug Administration reached an agreement with representatives of the medical device industry for proposed recommendations of the medical device user fee program.
In June, the CDC recommended against using AstraZeneca's nasal flu vaccine, FluMist, citing a lack of evidence regarding the vaccine's efficacy. FluMist's absence from the American market is causing some physicians to worry about a potential flu vaccine shortage.
The Food and Drug Administration submitted an annual report to Congress regarding the use of citizen petitions that allow the general public to ask the agency to refrain from approving a generic drug or biosimilar over potential health concerns, reported…
Senator Bernie Sanders (D-Vt.) responded to news of Pfizer's $14 billion acquisition of Medivation by calling on the drug industry to lower the cost of prescription drugs, reported CNN.
The Food and Drug Administration granted de novo clearance for ImPACT, a device used to assess cognitive function following possible concussion or brain injury.
International investors are increasingly bidding for biomedical laboratories in Boston in what they see as an opportunity to profit from increasing property values and rent, according to The Boston Globe.
In the fourth quarter of fiscal year 2016, Charlotte, N.C.-based Premier saw net revenue increase 13 percent from the same period last year to $301.4 million. Most notably, its supply chain services segment revenue rose 11 percent and its performance…
Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) wants answers —specifically, to why the price of EpiPens has jumped 400 percent since 2007, reported The Hill.
One in five heart attacks occurs outside of a hospital near an AED that is locked up or inaccessible, according to a study published in the Journal of the American College of Cardiology.
The Food and Drug Administration granted Fast Track designation for AZD3293, an experimental Alzheimer's drug created by Indianapolis-based Eli Lilly and Britain-based AstraZeneca.